CTOs on the Move


 
We cultivate authentic materials without compromise,by harnessing science and nature responsibly by partnering the most innovative minds in science and technology with the finest craftspeople to accelerate the use of cellular agriculture for good.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

VitroLabs raised $47.4M on 05/04/2022

Similar Companies

Prescott Medical Communications Group

Prescott Medical Communications Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adaptive Phage

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT`s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT`s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

HiFiBiO - High Fidelity Biology

HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.

Day One Biopharmaceuticals

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.

Carmell Therapeutics

Our groundbreaking plasma-based materials are designed to improve patient outcomes and reduce healthcare costs across a variety of surgical procedures.